SOMERSET, N.J. – November 27, 2018 - Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that work to expand its primary packaging capabilities at its clinical facility in Shanghai, China has reached the commissioning stage and is scheduled to be completed by the end of 2018.
The expansion includes a new automated, high-speed bottling line suitable for capsule and tablet products. The line will increase packaging capacity by up to 100 bottles per minute, and provides for quick and easy changeover, essential for clinical-scale production.
“Globally, almost 2,000 industry sponsored clinical trials were conducted in the last two years,” commented Roel de Nobel, Catalent’s Vice President, Global Operations, Clinical Supply Services. “Our continued investment in Asia Pacific reflects the importance of, and the continued growth of clinical trials in Asia, driving the need for in-region packaging services.”
This expansion follows the announcement that work is underway to open a new clinical facility outside of Shanghai’s free trade zone (FTZ). The new facility is expected to be completed in early 2019 and will join the company’s existing three clinical packaging facilities in the Asia Pacific region, namely in Shanghai’s Waigaoqiao FTZ, Singapore and Kakegawa, Japan. In addition to its primary packaging capabilities, the company offers comprehensive clinical supply solutions in the region including clinical supply management, comparator sourcing, FastChain® demand led supply, secondary packaging, storage and global distribution and clinical returns and destruction.
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.